ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2019

Dec 5, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Professor Carolyn Sue
Date of last notice	16 May 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	6 December 2019
No. of securities held prior to change	Nil
Class	Unlisted Options
Number acquired	600,000 unlisted options
Number disposed	Nil
Value/Consideration	Exercisable at $0.0188 per option and
Note: If consideration is non-cash, provide details and estimated valuation	expiring on 6 December 2023.
No. of securities held after change	600,000 unlisted options

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change

Nature of change Following shareholder approval at the Example: on-market trade, off-market trade, exercise of options, issue of annual general meeting held on 7 securities under dividend reinvestment plan, participation in buy-back November 2019, Professor Sue has been issued 600,000 options for nil consideration with an exercise price of $0.0188 with an expiry date of 6 December 2023. These options comprise a component of the Directors’ remuneration.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 317] intentionally omitted <==

----- Start of picture text ----- Detail of contract N/ANature of interestName of registered holder(if issued securities)Date of changeNo. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changedInterest acquiredInterest disposedValue/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuationInterest after change----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011